Sign In
Buy LTRN
$2.75
+0.140 (+5.36%)
At Close: Aug 04, 2026
Lantern Pharma Inc. (LTRN) Q4 2022 Earnings Call Transcript
11:57pm, Monday, 20'th Mar 2023
Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2022 Results Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Of
LTRN Stock: 7.74% Increase After Hours Explanation
11:25pm, Monday, 20'th Mar 2023
The stock price of Lantern Pharma Inc (NASDAQ: LTRN) increased by 7.74% after hours in the most recent trading session. This is why.
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
08:00am, Wednesday, 15'th Mar 2023
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“M
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
08:00am, Monday, 13'th Mar 2023
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) pl
Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week
06:16am, Monday, 13'th Mar 2023
Lantern Pharma Inc. LTRN, -13.13% confirmed Monday that it, or any of its subsidiaries, had no exposure to SIVB Financial Group's SIVB, -60.41% Silicon Valley Bank, Silvergate Capital Corp. SI, -11.27
7 AI Penny Stocks That Could Skyrocket in 2023
12:10pm, Tuesday, 21'st Feb 2023
AI penny stocks provide investors with higher-risk, higher-upside exposure to companies specializing in developing or utilizing artificial intelligence technology. Since these stocks trade at a rel
ProPhase Labs Discloses 8.4% Position in LTRN / Lantern Pharma After Q3 Results
10:31pm, Tuesday, 22'nd Nov 2022
Fintel reports that ProPhase Labs, Inc. has filed a 13G form with the SEC disclosing ownership of 910,000 shares of Lantern Pharma Inc. (LTRN). This represents 8.4% of the company.
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
07:00am, Friday, 21'st Oct 2022
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.
Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET
04:00pm, Tuesday, 11'th Oct 2022
DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine lea
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (�
DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (�
Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q2 2022 Results - Earnings Call Transcript
09:13pm, Monday, 08'th Aug 2022
Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Ma
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2022 Results - Earnings Call Transcript
10:40pm, Tuesday, 03'rd May 2022
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate, Finance & Administrative Coordinator Panna
Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET
07:00am, Friday, 22'nd Apr 2022
DALLAS, April 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning
LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. Brain metastases in the U.S. can occur in 10-30% of all cancer cases and are diagnosed in o
